Evidence map›Paper›PMID 42292227›Full record

ArticleFrontiers in medicine2026

Case Report: Successful treatment of

Sophie Pierson, Melchior Chabannes, Stéphane Lang, Mathilde Colladant, Jean Seibel, Jamal Bamoulid, Didier Ducloux, Cécile Courivaud, Sophie Felix, Thomas Crepin

Abstract readCase Reports
In one paragraph

Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sophie PiersonDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Melchior ChabannesDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Stéphane LangDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Mathilde ColladantDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Jean SeibelDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Jamal BamoulidDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Didier DuclouxDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Cécile CourivaudDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.
Sophie FelixDepartment of Pathology, University Hospital of Besançon, Besançon, France.
Thomas CrepinDepartment of Nephrology, Dialysis, and Renal Transplantation, University Hospital of Besançon, Besançon, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Infectious crescentic glomerulonephritis (CrGN) is a rare but severe complication in kidney transplant (KTx) recipients. Case presentation: A 64-year-old man with a history of two kidney transplants presented with a 3-week deterioration in renal function, progressing to nephritic syndrome (urine protein creatinine ratio (UPCR) 5.1 g/g, albumin 22 g/L, hypertension, and peripheral edema [+6 kg over 1 week]) and oliguric acute kidney injury (peak creatinine 684 μmol/L). Renal biopsy showed CrGN with IgM/IgA/C3 deposits, suggesting immune complex-mediated pathology. Initial investigations, including blood cultures, two transthoracic echocardiograms performed 1 week apart, and PET scan, ruled out infective endocarditis. Reinterrogation post-biopsy uncovered a cat bite 2 months prior, raising concerns for Management and outcome: The patient received azithromycin (500 mg/day for 5 days) for infection and corticosteroids (5 mg/kg pulse followed by a tapering regimen) for glomerulonephritis. After 2 dialysis sessions, renal function improved as evidenced by recovery urine output, which led to discontinuous of dialysis. A major complication (upper gastrointestinal bleeding) required endoscopic intervention and blood transfusions. Nephroprotective therapy was optimized (irbesartan up titrated from 75 to 150 mg/days and dapagliflozin 10 mg/day introduced), leading to normalization of proteinuria (UPCR 0.5 g/g) at 1-year follow-up. Conclusion: This case underscores the importance of reinterrogating patients for exposure risks (e.g., animal bites) when facing unexplained CrGN, particularly in renal transplant recipients. It also highlights the effectiveness of combined antibiotic and corticosteroids therapies in managing infectious glomerulonephritis. Clinicians should consider

Indexed as

Bartonella henselaecase reportcrescentic glomerulonephritisinfectious glomerulonephritisrenal transplantation

Identifiers

PMID42292227
PMCPMC13253307

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.